EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The role of CSNK1A1 and its de novo mutations in infantile spasms syndrome

Decheng Ren, Zhenxi Yang, Juan Hu, Lei Ji, Yan Bi, Fan Yuan, Yang Yan, Jing Peng, Keyi Li, Ke Yang, Liangjie Liu, Xiao Mao, Yingying Luo, Yanlin Wang, Guang He, Kai Li, Ying Peng

Human Molecular Genetics · 2025-05-06 · 34 (10) · 905-913

DOI: 10.1093/hmg/ddaf030 ↗
AbstractBibliografische Angaben

Abstract

Abstract Infantile spasms syndrome (ISS) is an early-onset epileptic encephalopathy characterized by uncontrollable seizures, severe electroencephalogram abnormalities, as well as delayed cognitive and behavioral development. Independent studies have shown that a variety of genes are involved in ISS and genetic factors play a critical role in its pathogenesis. Here we report two de novo mutations in the casein kinase 1 isoform alpha (CSNK1A1) gene which underlie severe epilepsy with similar clinical presentation in two patients. The identified variants are one missense mutation c.646G > C (p.Ala216Pro, Mut) in NM_001025105.3 and one deletion c.599_604delACATAC (p.His200_Ile201del, Del). In vitro analyses indicated that the Mut causes significant decreases in both mRNA and protein expression, while the Del demonstrated no significant impact on gene expression level. However, co-immunoprecipitation studies have shown that both mutations lead to reduced interactions between CSNK1A1 and β-catenin, resulting in excessive intracellular β-catenin and aberrant expression of several downstream genes. Compared with the wild type (WT), the EdU positive rates in cells transfected with Mut plasmid or Del plasmid were both elevated. Wnt/β-catenin signaling pathway is crucial to neurogenesis. An abnormal rise in β-catenin level has been utilized to generate genetic models for ISS. Our results not only elucidate the role of a novel candidate gene CSNK1A1 in the pathology of ISS, but also provide further evidence for the findings that mediating Wnt/β-catenin signaling is a potential mechanism causing ISS.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →